[Lornoxicam (xefocam) as an agent for the prevention and treatment of postoperative pain among other nonsteroidal anti-inflammatory drugs].

Lornoxicam (xefocam) as an agent of perioperative antinociceptive defense was studied and compared with other nonsteroidal anti-inflammatory drugs (NSAIDs) (ketorolac, ketoprofen). A comparative study was performed in 140 cancer surgical patients who were mainly middle-aged and elderly (51 +/- 10.9 years) and who had various concomitant diseases (ASA II-III).

[Use of analgesics with peripheral action in the system of complex protection of the patient from operative trauma].

Obtained for many years experience of perioperative using of analgesics with peripheral effect is summarized. The special scientific analysis was carried out in 274 patients who got different analgesics with peripheral action (aspisol, baralgin, ketoprofen, ketorolak, contrikal) at different stages of preoperative period in combination with opioid. The control group included 30 patients who got monoanalgesia by promedol after abdominal operations.

[Ketoprofen (ketonal): a drug for preventing and treating postoperative pain].

A prophylactic approach to the management of postoperative pain is described: ketoprofen, a nonsteroid antiinflammatory drug, was used, which possesses numerous advantages and a variety of dosage forms. To cancer patients subjected to extensive radical operations on the pelvic organs, head, and neck, ketonal (ketoprofen) was injected intramuscularly or rectally in a dose of 100 mg 1 h before surgery and in a daily dose of 300 mg during the postoperative period. Adequate postoperative monoanalgesia with ketonal was attained in 47% patients.

[Preventive analgesia: a new trend in anesthesiology. An idea born and developed at the P.A. Herzen Institute of Oncology].

The authors summarize positive experience gained in the use of preventive anesthesia in oncosurgery. The new trend in anesthesiology has been developed at P. A.

[Butorfanol tartrate (beforol) in cancer surgery].

The results of the clinical study of beforal (butorfanol) ("Spofa", Czechoslovakia), a synthetic analgetic from a class of opiate agonists-antagonists, in 17 cancer patients at all stages of surgical treatment have been summarized. It has been established that beforal is a potent analgetic analogous in antistressor properties to moradol ("Galenika", Yugoslavia), however differing by a more prompt onset and discontinuation of action, thus improving the control over general anesthesia. A comparative assessment of circulation parameters and stress factors (glucose, cortisol, blood plasma STH) has shown that beforal exceeds fentanyl in the efficacy of prevention of surgical trauma during and after extended cancer surgery.